Biotech Companies

297 companies | Drug discovery and development companies

#	COMPANY	THERAPEUTIC AREAS	STAGE
1.	4D Pharma plc Leeds, United Kingdom	Oncology Immunology Gastroenterology	Preclinical to Phase II (at time of administration)	VIEW
2.	ADMA Biologics, Inc. Ramsey, New Jersey, United States		Commercial + Preclinical	VIEW
3.	AGS Therapeutics Paris, France	Ophthalmology Immunology Infectious Disease+2	Preclinical	VIEW
4.	Aardvark Therapeutics San Diego, USA	Rare Diseases Metabolic	Phase 3	VIEW
5.	Abivax Paris, France	Immunology Gastroenterology	Phase 3	VIEW
6.	Acadia Pharmaceuticals Inc. San Diego, USA	Neuroscience Rare Diseases	Commercial	VIEW
7.	Acelot South San Francisco, California, USA	Metabolic Oncology	Preclinical	VIEW
8.	Acrux Melbourne, Australia	Dermatology Metabolic	Commercial	VIEW
9.	Affitech Copenhagen, Denmark (with R&D in Oslo, Norway and San Francisco, USA)	Oncology Immunology Infectious Disease	Clinical	VIEW
10.	Agios Pharmaceuticals Cambridge, USA	Rare Diseases Hematology Metabolic	Commercial	VIEW
11.	Agomab Therapeutics Antwerp, Belgium	Gastroenterology Rare Diseases	Phase 2	VIEW
12.	Ajou University Suwon, South Korea	Oncology Immunology Neuroscience+2	Phase 3	VIEW
13.	Akribes Biomedical Vienna, Austria	Dermatology	Preclinical	VIEW
14.	Alkeus Pharmaceuticals Cambridge, USA	Ophthalmology Rare Diseases	Phase 3	VIEW
15.	Allergy Therapeutics Worthing, United Kingdom		Phase 3 and Phase 1/2	VIEW
16.	Allygen Biosciences Shanghai, China	Oncology Immunology	Preclinical	VIEW
17.	Anavex Life Sciences Corp. New York, United States	Oncology	Phase 2\|Phase 3	VIEW
18.	Aquinas Companies, LLC (Fannin Innovation Studio) Houston, Texas, USA	Oncology Infectious Disease Cardiovascular+2	Phase 2	VIEW
19.	Arcus Biosciences Hayward, United States	Oncology Immunology	Phase 3	VIEW
20.	Ardelyx Waltham, Massachusetts, USA	Gastroenterology	Commercial	VIEW
21.	Artica Therapeutics Leiden, Netherlands	Immunology	Preclinical	VIEW
22.	Artificial Axon Labs Cambridge, Massachusetts, USA	Neuroscience	Discovery	VIEW
23.	AskGene Camarillo, California, United States	Oncology Immunology Ophthalmology	Phase 3	VIEW
24.	Asklepion Pharmaceuticals, LLC Baltimore, Maryland, USA		Phase 3	VIEW
25.	Asklepios BioPharmaceutical Research Triangle Park, North Carolina, USA	Metabolic	Phase 1\|Phase 2\|Preclinical	VIEW
26.	Aspen Global Incorporated Grand Bay, Mauritius	Oncology Cardiovascular Metabolic+1	Commercial	VIEW
27.	AtaiBeckley (formerly ATAI Life Sciences) Berlin, Germany (original); U.S. redomiciliation completed December 30, 2025		Phase 2	VIEW
28.	Autolus Therapeutics London, United Kingdom	Oncology Immunology Rare Diseases	Commercial + Phase 1/2	VIEW
29.	Avenzo Therapeutics San Diego, USA	Oncology	Phase 2	VIEW
30.	Azurity Pharmaceuticals Woburn, USA	Cardiovascular Metabolic Gastroenterology+2	Commercial	VIEW
31.	B.Grimm Pharma Bangkok, Thailand	Cardiovascular Gastroenterology Infectious Disease+1	Commercial	VIEW
32.	BRIM Biotechnology, Inc. Taipei, Taiwan	Ophthalmology Rare Diseases	Phase 3	VIEW
33.	BeOne Medicines (formerly BeiGene) Cambridge, Massachusetts, United States (corporate); Basel, Switzerland (post-redomiciliation May 2025)	Oncology	Phase 1-3 and Commercial	VIEW
34.	BenevolentAI London, United Kingdom	Oncology Immunology Neuroscience+3	Phase 1\|Phase 2\|Preclinical	VIEW
35.	Berg Health Framingham, Massachusetts, USA	Oncology Neuroscience Rare Diseases	Phase 1/2	VIEW
36.	Bharat Biotech Hyderabad, India	Infectious Disease Oncology	Commercial	VIEW
37.	BioCardia, Inc. Sunnyvale, California, USA	Cardiovascular Respiratory	Phase 3	VIEW
38.	BioMed Valley Discoveries Kansas City, Missouri, USA	Oncology Immunology Rare Diseases+1	Clinical (Phase 1-2)	VIEW
39.	Biomea Fusion San Carlos, USA	Metabolic Oncology	Phase 2	VIEW
40.	Biotest AG Dreieich (Frankfurt), Germany	Hematology	Phase 3/Commercial	VIEW
41.	Biotest AG Dreieich, Germany	Hematology	Phase 2\|Phase 3\|Commercial	VIEW
42.	BlueRock Therapeutics Cambridge, USA	Neuroscience Cardiovascular Ophthalmology+1	Phase 3	VIEW
43.	Boostimmune Seoul, South Korea	Oncology Immunology	Preclinical	VIEW
44.	Bota Biosciences Hangzhou, China (International HQ in Lafayette, CA, USA)		Commercial	VIEW
45.	CDR-Life Schlieren, Zurich, Switzerland	Oncology Immunology Ophthalmology	Phase 1	VIEW
46.	CECOS University of Information Technology and Emerging Sciences Peshawar, Pakistan	Oncology Neuroscience Infectious Disease	Preclinical	VIEW
47.	CEPI Oslo, Norway	Infectious Disease	Commercial	VIEW
48.	CHUV (Centre Hospitalier Universitaire Vaudois) Lausanne, Switzerland	Oncology Immunology Neuroscience+2	Phase 3	VIEW
49.	Caldera Therapeutics Cambridge, USA	Immunology Gastroenterology	Phase 1	VIEW
50.	Calico Life Sciences South San Francisco, United States	Oncology Neuroscience Immunology	Phase 2	VIEW
51.	Cantargia AB Lund, Sweden	Oncology Immunology	Phase 1 - Phase 2	VIEW
52.	Cardurion Pharmaceuticals Burlington, United States	Cardiovascular	Phase 2	VIEW
53.	Carrick Therapeutics Dublin, Ireland	Oncology	Phase 2	VIEW
54.	Cell-Tx Seoul, South Korea	Neuroscience Oncology Ophthalmology	Preclinical	VIEW
55.	Celon Pharma Łomianki, Poland	Neuroscience Oncology Immunology+1	Phase 3	VIEW
56.	Celularity Inc Florham Park, New Jersey, USA	Oncology	Phase 1/2 and Phase 2	VIEW
57.	Center for Neuromusculoskeletal Restorative Medicine Limited Shatin, Hong Kong	Neuroscience Rare Diseases	Preclinical	VIEW
58.	Center of Molecular Immunology (CIM) Havana, Cuba	Oncology Immunology	Commercial	VIEW
59.	Centrexion Therapeutics Boston, Massachusetts, United States	Immunology	Phase 1-3	VIEW
60.	Cerevel Therapeutics Cambridge, Massachusetts, USA		Phase 1-3	VIEW
61.	Chengdu Kanghong Pharmaceutical Group Chengdu, China	Ophthalmology Neuroscience Oncology	Commercial	VIEW
62.	Chiba University Chiba, Japan	Oncology Immunology Rare Diseases+3	Phase 2	VIEW
63.	China Medical University Hospital (CMUH) Taichung, Taiwan	Oncology Neuroscience Cardiovascular+2	Phase 2	VIEW
64.	Chongqing PegBio Biotechnology Co., Ltd. Chongqing, China	Gastroenterology Hematology Oncology	Phase 3	VIEW
65.	Choose Life Biotech SA Bellinzona, Switzerland	Immunology Infectious Disease Oncology	Preclinical	VIEW
66.	Chung-Ang University Seoul, South Korea	Oncology Cardiovascular Immunology+2	Phase 3	VIEW
67.	Cincinnati Children's Hospital Medical Center Cincinnati, USA	Oncology Immunology Rare Diseases+4	Commercial	VIEW
68.	Circio Holding ASA Lysaker, Norway	Oncology Immunology Gene Therapy	Phase 1/2	VIEW
69.	City of Hope Duarte, California, USA	Oncology Hematology Rare Diseases	Commercial	VIEW
70.	Clasp Therapeutics Rockville, Maryland, USA	Oncology	Phase 1	VIEW
71.	Codexis, Inc. Redwood City, California, USA	Rare Diseases Metabolic	Commercial	VIEW
72.	Constructor Group Schaffhausen, Switzerland	Oncology Infectious Disease Neuroscience	Preclinical	VIEW
73.	Corline Biomedical AB Uppsala, Sweden	Metabolic Cardiovascular Neuroscience	Phase 2	VIEW
74.	Cosmo Pharmaceuticals N.V. Dublin, Ireland	Gastroenterology Dermatology Infectious Disease	Commercial	VIEW
75.	Crixmor LLC Malvern, Pennsylvania, USA	Immunology Gastroenterology Oncology	Discovery	VIEW
76.	Cugene Inc. Waltham, USA	Oncology Immunology	Phase 1	VIEW
77.	Cullinan Therapeutics Cambridge, USA	Oncology Immunology	Phase 3	VIEW
78.	CuraTeQ Biologics Hyderabad, India	Oncology Immunology Metabolic	Commercial	VIEW
79.	CuraVac Rixensart, Belgium	Immunology	Phase 1B (completed) \| Phase 2 (in preparation)	VIEW
80.	Curadev Pharma Pvt Ltd Noida, India	Oncology Immunology Metabolic	Phase 1	VIEW
81.	Curasight Copenhagen, Denmark	Oncology	Phase 1-2 Clinical	VIEW
82.	Curatis Liestal, Switzerland	Oncology Neuroscience Respiratory+1	Phase 3	VIEW
83.	Curative Biotechnology Inc Boca Raton, Florida, USA	Infectious Disease	Pre-Clinical\|IND-Enabling Studies	VIEW
84.	CureVac Tübingen, Germany	Oncology Infectious Disease Rare Diseases	Phase 2	VIEW
85.	CytoAgents Pittsburgh, USA	Oncology Immunology Infectious Disease+1	Phase 2	VIEW
86.	CytoDyn Inc Vancouver, Washington	Oncology Immunology	Phase 2 clinical	VIEW
87.	CytoImmune Therapeutics Duarte, USA	Oncology Hematology Immunology	Phase 1	VIEW
88.	CytoSen Therapeutics Orlando (Winter Springs), Florida, USA	Oncology Cell Therapy Immunology	Phase 2	VIEW
89.	CytoTools AG Heidelberg, Germany	Dermatology Cardiovascular Oncology	Phase 3	VIEW
90.	CytoVac Hørsholm, Denmark	Oncology	Phase 2	VIEW
91.	Cytochroma Edinburgh, United Kingdom	Cardiovascular Rare Diseases	Discovery	VIEW
92.	Cytocom, Inc. Fort Collins, Colorado, USA	Oncology Infectious Disease Hematology+1	Phase 2/Phase 3	VIEW
93.	CytomX Therapeutics, Inc. South San Francisco, California, United States	Oncology	Phase 1 (clinical), Preclinical (discovery collaborations)	VIEW
94.	Cytonics Corporation Jupiter, Florida, USA	Immunology	Phase 2	VIEW
95.	Cytonus Therapeutics Carlsbad, California, United States	Oncology Immunology Infectious Disease+1	Phase 1	VIEW
96.	Cytorex Biosciences Weston, Florida, USA	Oncology Metabolic Infectious Disease	Preclinical	VIEW
97.	Cytovation Bergen, Norway	Oncology Rare Diseases	Phase I/II - Phase II	VIEW
98.	Cytovia Therapeutics Aventura, Florida, USA	Oncology Immunology	Phase 1/2	VIEW
99.	Cyxone Malmö, Sweden	Immunology Neuroscience	Phase 2	VIEW
100.	DBV Technologies Châtillon, France	Immunology	Phase 3	VIEW
101.	Dendreon Pharmaceuticals Seal Beach, USA	Oncology	Commercial	VIEW
102.	Development Center for Biotechnology (DCB) Taipei, Taiwan	Oncology Immunology Infectious Disease	Preclinical	VIEW
103.	Dexcel Pharma Or Akiva, Israel	Oncology Cardiovascular Neuroscience+2	Commercial	VIEW
104.	DifGen Pharmaceuticals Miramar, USA	Ophthalmology Neuroscience	Commercial	VIEW
105.	Differential Bio Munich, Germany		Commercial	VIEW
106.	Dolor Therapeutics, Inc. Chicago, USA	Immunology	Preclinical	VIEW
107.	Drugs for Neglected Diseases initiative (DNDi) Geneva, Switzerland	Infectious Disease	Commercial	VIEW
108.	Duality Biologics Shanghai, China	Oncology Immunology	Phase 3	VIEW
109.	E-Flask Seongnam, South Korea	Neuroscience Oncology	Phase 1	VIEW
110.	EEE Pharma Maharashtra, India	Infectious Disease Immunology Cardiovascular+1	Commercial	VIEW
111.	ETH Zürich Zurich, Switzerland	Oncology Immunology Neuroscience+4	Discovery	VIEW
112.	EUBREAST Esslingen, Germany	Oncology	Phase 3	VIEW
113.	Edge Therapeutics, Inc. Princeton, New Jersey, USA	Oncology Infectious Disease	Phase 3	VIEW
114.	Eledon Pharmaceuticals Irvine, USA	Immunology	Phase 2	VIEW
115.	Eleven Therapeutics Cambridge, United Kingdom	Infectious Disease	Discovery	VIEW
116.	Ellipses Pharma London, United Kingdom	Oncology	Phase 1/2	VIEW
117.	Emergent BioSolutions Gaithersburg, Maryland, USA	Infectious Disease	Commercial	VIEW
118.	Eneapharm Labège, France	Gastroenterology Rare Diseases	Clinical	VIEW
119.	Enlivex Therapeutics Ltd. Ness Ziona, Israel	Immunology Oncology Infectious Disease	Phase 2	VIEW
120.	Entact Bio Watertown, USA	Oncology Immunology Rare Diseases	Preclinical	VIEW
121.	EurimPharm Arzneimittel GmbH Saaldorf-Surheim, Germany	Oncology Immunology Neuroscience+2	Commercial	VIEW
122.	Evotec SE Hamburg, Germany	Oncology Neuroscience Infectious Disease+1	Commercial	VIEW
123.	Exelixis Alameda, USA	Oncology	Commercial	VIEW
124.	Exeltis Florham Park, USA (Global HQ in Madrid, Spain)	Neuroscience Respiratory Dermatology+2	Commercial	VIEW
125.	FNCT Biotech Seongnam-si, South Korea	Oncology Immunology	Preclinical	VIEW
126.	Flare Therapeutics Cambridge, MA, USA	Oncology	Phase 1-1B	VIEW
127.	Focus Care Pharmaceuticals B.V. Zaandam, Netherlands	Respiratory Neuroscience Cardiovascular+1	Commercial	VIEW
128.	Forma Therapeutics Inc Watertown, USA	Hematology Oncology Rare Diseases	Phase 3	VIEW
129.	Formation Bio New York, USA	Immunology Dermatology Neuroscience	Phase 3	VIEW
130.	Formycon AG Planegg-Martinsried, Germany	Ophthalmology Immunology	Commercial	VIEW
131.	Frontier Medicines South San Francisco, USA	Oncology Immunology	Phase 1/2	VIEW
132.	Fusion Pharmaceuticals Inc. Hamilton, Ontario, Canada	Oncology	Phase 1\|Phase 2\|Phase 3	VIEW
133.	G. H. Raisoni University Saikheda, India	Oncology Metabolic Neuroscience+1	Discovery	VIEW
134.	Galpha Laboratories Limited Mumbai, India	Infectious Disease Gastroenterology Dermatology	Commercial	VIEW
135.	Gan & Lee Pharmaceuticals Beijing, China	Metabolic Oncology Cardiovascular	Commercial	VIEW
136.	GenAns Biotech Beijing, China	Neuroscience Ophthalmology Oncology	Preclinical	VIEW
137.	Gene Oasis Singapore, Singapore	Oncology Neuroscience Immunology+1	Clinical	VIEW
138.	GeneBiology, Inc. Research Triangle Park, North Carolina, USA	Oncology Neuroscience Gastroenterology	Clinical	VIEW
139.	Genentech South San Francisco, California, United States	Oncology Immunology Rare Diseases+3	Discovery through Commercial	VIEW
140.	George Mason University Fairfax, USA	Oncology Infectious Disease Metabolic+2	Phase 2	VIEW
141.	Georgia Southern University Statesboro, USA	Oncology Infectious Disease Neuroscience+1	Discovery	VIEW
142.	Gesynta Pharma AB Stockholm, Sweden		Phase 2	VIEW
143.	Ghosts Past		-	VIEW
144.	Google (Google DeepMind / Isomorphic Labs) London, United Kingdom	Oncology Immunology Cardiovascular	Preclinical	VIEW
145.	HBM Partners Zug, Switzerland	Oncology Immunology Neuroscience+3	Commercial	VIEW
146.	HCW Biologics Inc. Miramar, Florida, USA	Oncology Immunology	Phase 2	VIEW
147.	HGFH (Placeholder Entity) N/A		Discovery	VIEW
148.	Halozyme Therapeutics San Diego, USA	Oncology Immunology Neuroscience+3	Commercial	VIEW
149.	Hamad Bin Khalifa University (HBKU) Doha, Qatar	Oncology Metabolic Infectious Disease+1	Preclinical	VIEW
150.	Hansa Biopharma Lund, Sweden	Immunology Gene Therapy Oncology	Commercial	VIEW
151.	Hanyang University Seoul, South Korea	Oncology Neuroscience Infectious Disease+1	Phase 2	VIEW
152.	Healios K.K. Tokyo, Japan	Neuroscience Oncology Ophthalmology	Phase 3	VIEW
153.	Healis Therapeutics Cambridge, USA	Neuroscience	Phase 2/3	VIEW
154.	Heligenics Phoenix, Arizona, USA	Oncology Rare Diseases	Discovery	VIEW
155.	Hemerion Therapeutics Villeneuve d'Ascq, France	Oncology	Phase 1/2	VIEW
156.	Hevolution Foundation Riyadh, Saudi Arabia	Oncology Neuroscience Rare Diseases	Discovery	VIEW
157.	Holostem S.r.l. Modena, Italy	Ophthalmology Dermatology Rare Diseases	Commercial	VIEW
158.	Hone Bio Bristol, United Kingdom	Oncology Cardiovascular	Preclinical	VIEW
159.	Hudson Pharmaceuticals Ltd. Dhaka, Bangladesh	Respiratory Ophthalmology Gastroenterology+2	Commercial	VIEW
160.	Huons Co., Ltd. Seongnam, South Korea	Ophthalmology Metabolic	Commercial	VIEW
161.	IMTR Inc. Tokyo, Japan	Immunology Hematology Gastroenterology	Phase 1/2	VIEW
162.	ITESO, Universidad Jesuita de Guadalajara Tlaquepaque, Mexico		Discovery	VIEW
163.	Idorsia Allschwil, Switzerland	Neuroscience Cardiovascular Immunology+1	Commercial	VIEW
164.	Immorna Biotherapeutics Morrisville, USA	Oncology Infectious Disease Dermatology+1	Phase 2	VIEW
165.	Immuneel Therapeutics Bengaluru, India	Oncology Hematology Immunology	Commercial	VIEW
166.	Immunomic Therapeutics, Inc. Rockville, Maryland, United States	Oncology Infectious Disease	Phase 1 - Phase 2	VIEW
167.	Indian Immunologicals Limited Hyderabad, India	Infectious Disease Immunology	Commercial	VIEW
168.	Infinitopes Oxford, United Kingdom	Oncology	Phase 1/IIa	VIEW
169.	Initial Therapeutics South San Francisco, USA	Oncology Rare Diseases	Discovery	VIEW
170.	Intellia Therapeutics Cambridge, USA	Rare Diseases Cardiovascular Neuroscience+2	Phase 3	VIEW
171.	Intelligene Taipei, Taiwan	Infectious Disease	Phase 1	VIEW
172.	International Livestock Research Institute (ILRI) Nairobi, Kenya	Infectious Disease	Commercial	VIEW
173.	Inventiva Pharma Daix, France	Oncology	Phase 3	VIEW
174.	Ionis Pharmaceuticals, Inc. Carlsbad, California, United States	Neuroscience Cardiovascular Immunology+1	Phase 1 through Commercial	VIEW
175.	Janux Therapeutics San Diego, California, USA	Oncology Immunology	Phase 1	VIEW
176.	Jiayue Pharmaceutical Guangzhou, China	Oncology Immunology Infectious Disease	Phase 3	VIEW
177.	Junshi Biosciences Shanghai, China	Oncology Immunology Metabolic+1	Commercial	VIEW
178.	KM Biologics Co., Ltd. Kumamoto, Japan	Infectious Disease Hematology Immunology	Commercial	VIEW
179.	Kenai Therapeutics San Diego, USA	Neuroscience	Phase 1	VIEW
180.	Khartis Therapeutics, Inc. San Diego, USA	Immunology	Discovery	VIEW
181.	Kiniksa Pharmaceuticals London, United Kingdom	Cardiovascular Immunology Rare Diseases	Commercial	VIEW
182.	Knight Therapeutics Inc. Montreal, Canada	Oncology Hematology Infectious Disease+2	Commercial	VIEW
183.	Kura Oncology Inc San Diego, California, USA	Oncology	Phase 1\|Phase 2\|Phase 3\|Approved	VIEW
184.	Kyung Hee University Seoul, South Korea	Oncology Neuroscience Immunology+1	Phase 3	VIEW
185.	LG Business Research Seoul, South Korea	Oncology Immunology Vaccines	Commercial	VIEW
186.	Laboratorios Bagó Buenos Aires, Argentina	Oncology Hematology Cardiovascular+3	Commercial	VIEW
187.	Laboratorios Viñas Barcelona, Spain	Dermatology	Commercial	VIEW
188.	Laurent Pharmaceuticals Montreal, Quebec, Canada		Phase 2/3	VIEW
189.	Medac GmbH Wedel, Germany	Oncology Hematology Immunology	Commercial/Phase 3	VIEW
190.	MedinCell Montpellier, France		Commercial\|Phase 3\|Preclinical	VIEW
191.	Medison Pharma Petah Tikva, Israel	Oncology Rare Diseases Immunology+2	Commercial	VIEW
192.	Menarini Stemline New York, USA	Oncology Hematology Rare Diseases	Commercial	VIEW
193.	Mersana Therapeutics Cambridge, USA	Oncology Rare Diseases	Phase 1	VIEW
194.	Merus N.V. Utrecht, Netherlands	Oncology	Commercial (BLA Stage)	VIEW
195.	Mesa Green Pharma Frederick, USA	Neuroscience	Preclinical	VIEW
196.	Metagenomi Emeryville, USA	Hematology Cardiovascular Rare Diseases+1	Preclinical	VIEW
197.	Micro CRISPR Vapi, India	Oncology Hematology Metabolic+1	Preclinical	VIEW
198.	Miltenyi Biotec Bergisch Gladbach, Germany	Oncology Immunology Hematology	Commercial	VIEW
199.	Mirum Pharmaceuticals Foster City, USA	Rare Diseases	Commercial	VIEW
200.	Moderna Cambridge, USA	Infectious Disease Oncology Rare Diseases+2	Commercial	VIEW
201.	Mogam Institute for Biomedical Research Seoul, South Korea	Rare Diseases Infectious Disease Oncology+1	Discovery\|Preclinical	VIEW
202.	N4 Pharma Chellaston, Derbyshire, United Kingdom	Oncology	Preclinical	VIEW
203.	NBE Therapeutics Basel, Switzerland	Oncology	Phase 1/2	VIEW
204.	NEOM Tabuk, Saudi Arabia		Commercial	VIEW
205.	Nanocan Therapeutics Corporation Princeton, New Jersey (also noted as National Harbor, MD)	Oncology	Phase I/II	VIEW
206.	Nanophoria Milan, Italy	Cardiovascular Rare Diseases	Preclinical	VIEW
207.	Nanoscope Therapeutics Dallas, USA	Ophthalmology	Commercial	VIEW
208.	Natural Remedies Bangalore, India	Dermatology	Commercial	VIEW
209.	Nerviano Medical Sciences Nerviano, Italy	Oncology Hematology	Phase 2	VIEW
210.	Neurocrine Biosciences San Diego, USA	Neuroscience Metabolic Rare Diseases	Commercial	VIEW
211.	Neurogene Inc. New York, NY	Neuroscience Rare Diseases	Phase 2	VIEW
212.	NextCure, Inc. Beltsville, Maryland, USA	Oncology Immunology	Phase 2	VIEW
213.	Nexus Bio Sydney, Australia	Oncology Immunology Cell Therapy+1	Commercial	VIEW
214.	Notogen Inc. Toronto, Canada		Preclinical	VIEW
215.	NovaDigm Consulting Group Rockville, Maryland, USA	Infectious Disease Dermatology	Phase 2	VIEW
216.	Noveome Biotherapeutics Pittsburgh, Pennsylvania, USA	Ophthalmology Neuroscience Dermatology	Phase 1-2	VIEW
217.	Novonesis Lyngby, Denmark		Commercial	VIEW
218.	Nutshell Therapeutics Shanghai, China (Pudong District, Building E, No. 1976 Middle Gaoke Road)	Oncology	Preclinical to Phase 1	VIEW
219.	Nuvation Bio New York, United States	Oncology	Commercial	VIEW
220.	OSIVAX Lyon, France		Phase 2	VIEW
221.	Oban BioPharma Stamford, USA	Neuroscience	Preclinical	VIEW
222.	Ocular Therapeutix, Inc. Bedford, Massachusetts, USA	Ophthalmology	Commercial	VIEW
223.	On/Off Therapeutics Paris, France	Oncology Immunology Rare Diseases	Preclinical	VIEW
224.	OncoWise Bio Sydney, Australia	Oncology	Discovery	VIEW
225.	Oncotelic Therapeutics Agoura Hills, California, USA	Oncology Rare Diseases	Phase 1\|Phase 2\|Phase 3	VIEW
226.	Orchard Therapeutics London, United Kingdom	Immunology Rare Diseases	Commercial	VIEW
227.	Panion & BF Biotech Inc. Taipei, Taiwan	Dermatology Infectious Disease Gastroenterology	Commercial	VIEW
228.	Partex NV Eschborn, Germany	Oncology Neuroscience Rare Diseases+1	Phase 2	VIEW
229.	Parvus Therapeutics South San Francisco, USA	Immunology Gastroenterology Metabolic	Phase 1/2	VIEW
230.	Phanes Therapeutics San Diego, California, USA	Oncology	Phase 1/2	VIEW
231.	Phanes Therapeutics, Inc. San Diego, California, USA	Oncology	Phase 1/2	VIEW
232.	PharmaResearch Co., Ltd. Seongnam-si, South Korea	Ophthalmology	Commercial	VIEW
233.	Pharmaforce (Pty) Ltd Midrand, South Africa		Commercial	VIEW
234.	Pherecydes Pharma SA Romainville, France	Infectious Disease	Phase 2	VIEW
235.	Phibro Animal Health Corporation Teaneck, New Jersey, USA		Commercial	VIEW
236.	Platinum Life Excellence Biotech Beijing, China	Immunology Hematology	Commercial	VIEW
237.	Prana Biosciences Worcester, USA	Oncology Immunology	Preclinical	VIEW
238.	Quell Therapeutics London, United Kingdom	Immunology	Phase 2	VIEW
239.	QureBio Shanghai, China	Oncology Immunology	Phase 2	VIEW
240.	RNALead Toulouse, France	Oncology Immunology Infectious Disease	Phase 1	VIEW
241.	Rasan Pharmaceutical Industries Sulaymaniyah, Iraq	Infectious Disease	Commercial	VIEW
242.	Revolution Medicines Redwood City, USA	Oncology	Phase 3	VIEW
243.	Ribon Therapeutics Cambridge, MA, United States	Oncology Dermatology Respiratory	Phase 1/2	VIEW
244.	Ridgeline Discovery Basel, Switzerland	Oncology Immunology Metabolic+2	Discovery\|Preclinical\|Phase 1\|Phase 2	VIEW
245.	Rondo Therapeutics Hayward, USA	Oncology Immunology	Phase 1	VIEW
246.	SIFI Aci Sant'Antonio (Catania), Italy	Ophthalmology	Commercial	VIEW
247.	SNIPR Biome Copenhagen, Denmark	Infectious Disease Metabolic	Phase 1b-2a	VIEW
248.	Saol Therapeutics Roswell, USA	Neuroscience Rare Diseases	Phase 3	VIEW
249.	Scenic Biotech Amsterdam, The Netherlands	Oncology Immunology Rare Diseases+1	Preclinical to IND-enabling	VIEW
250.	Secura Bio Las Vegas, USA	Oncology Hematology	Commercial	VIEW
251.	Senti Biosciences South San Francisco, California, USA	Oncology Immunology	Phase 1	VIEW
252.	Sentien Biotech Lexington, Massachusetts, United States		Phase 1/2	VIEW
253.	Sentinel Oncology Cambridge, United Kingdom	Oncology	Preclinical to Phase 1	VIEW
254.	Shanghai Jeyou Pharmaceutical Co., Ltd. Shanghai, China (Pudong district)	Oncology Respiratory Immunology	Preclinical to Phase 2	VIEW
255.	SinSa Labs Lidingö, Sweden	Infectious Disease Ophthalmology Dermatology	Preclinical	VIEW
256.	Sinotherapeutics Inc. Shanghai, China	Oncology Neuroscience Gastroenterology	Commercial	VIEW
257.	Soleno Therapeutics, Inc. Redwood City, California, USA	Metabolic	Commercial	VIEW
258.	Southern Taiwan University of Science and Technology (STUST) Tainan City, Taiwan	Oncology	Preclinical	VIEW
259.	Spur Therapeutics London, United Kingdom		Phase 1/2 to Phase 3	VIEW
260.	StemGen Milan, Italy	Oncology	Phase 1/Phase 2	VIEW
261.	StemSynergy Therapeutics Miami, Florida, USA	Oncology Rare Diseases	Preclinical and IND-enabling	VIEW
262.	Stemline Therapeutics, Inc. New York, United States	Oncology	Commercial + Clinical Development	VIEW
263.	Stoke Therapeutics Bedford, USA (Moving to Waltham, MA in late 2026)	Neuroscience Ophthalmology Rare Diseases	Phase 3	VIEW
264.	Symmetra Bio Doha, Qatar	Cardiovascular	Discovery	VIEW
265.	TAE Life Sciences Irvine, California, United States	Oncology	Investigator Initiated Trials (IIT) - Early clinical stage	VIEW
266.	TRB Pharma Campinas, Brazil	Ophthalmology Neuroscience Dermatology	Commercial	VIEW
267.	TRG Ventures Hellerup, Denmark	Dermatology Immunology Neuroscience	Phase 3	VIEW
268.	TRIM-edicine, Inc. Columbus, Ohio, USA	Cardiovascular Dermatology	Preclinical	VIEW
269.	TS-VV GmbH Baesweiler, Germany		N/A	VIEW
270.	TVAX Biomedical, Inc. Lenexa, Kansas, United States	Oncology	Phase 2b/3	VIEW
271.	TYG Oncology Mansfield, Nottinghamshire, United Kingdom	Oncology Immunology	Phase 1	VIEW
272.	Tagworks Pharmaceuticals Nijmegen, Netherlands	Oncology	Phase 1	VIEW
273.	Tamkang University New Taipei City, Taiwan	Oncology Neuroscience Infectious Disease	Discovery	VIEW
274.	TechnoPhage Lisbon, Portugal	Infectious Disease Ophthalmology	Phase 1/IIa through Phase 3 in development	VIEW
275.	Terran Biosciences Miami Beach, Florida, USA		Phase 1\|Phase 2\|Phase 3\|Commercial (NM-101 FDA cleared)	VIEW
276.	Théa Open Innovation Clermont-Ferrand, France	Ophthalmology	Phase 1\|Phase 2\|Phase 3	VIEW
277.	Tongji University Shanghai, China	Oncology Cardiovascular Neuroscience	Phase 3	VIEW
278.	Tvardi Therapeutics Inc Sugar Land/Houston, Texas, USA	Oncology	Phase 2	VIEW
279.	U.S. Stem Cell, Inc. Sunrise, Florida, United States	Cardiovascular Immunology	Clinical Development	VIEW
280.	UC San Diego Health La Jolla, USA	Oncology Cardiovascular Neuroscience+1	Commercial	VIEW
281.	Ultragenyx Pharmaceutical Inc. Novato, USA	Rare Diseases	Commercial	VIEW
282.	University of British Columbia Vancouver, Canada	Oncology Infectious Disease Rare Diseases+1	Discovery	VIEW
283.	University of California, Berkeley Berkeley, USA	Oncology Immunology Neuroscience+1	Discovery	VIEW
284.	University of Cincinnati Cincinnati, USA	Oncology Neuroscience Hematology+2	Commercial	VIEW
285.	University of Colorado Boulder Boulder, USA	Oncology Rare Diseases Immunology+1	Discovery	VIEW
286.	University of Essex Colchester, United Kingdom	Oncology Neuroscience Immunology+1	Discovery	VIEW
287.	University of Wisconsin–Madison Madison, USA	Oncology Neuroscience Rare Diseases+3	Commercial	VIEW
288.	Vasa Therapeutics Encinitas, USA	Cardiovascular Metabolic	Phase 1	VIEW
289.	Vaxcyte San Carlos, California, USA	Infectious Disease Immunology	Clinical (Phase 2 and Phase 3)	VIEW
290.	Vertex Pharmaceuticals Boston, USA		Commercial	VIEW
291.	Visterra Waltham, USA	Immunology Infectious Disease Oncology	Phase 3	VIEW
292.	Vitane Pharmaceuticals Dubai, United Arab Emirates	Cardiovascular Neuroscience Gastroenterology+1	Commercial	VIEW
293.	X4 Pharmaceuticals Boston, USA	Immunology Hematology Rare Diseases+1	Commercial	VIEW
294.	Xilio Therapeutics Waltham, Massachusetts	Oncology Immunology	Phase 2	VIEW
295.	Yeditepe University Istanbul, Turkey	Oncology Neuroscience	Phase 3	VIEW
296.	Zenagem Philadelphia, Pennsylvania	Oncology Neuroscience Infectious Disease	Discovery	VIEW
297.	arGenX (argenx) Amsterdam, Netherlands	Immunology	Phase 1 through Commercial	VIEW